Clinical Trial

Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is an open, multicenter phase I/II clinical study. The entire study is divided into three stages: dose escalation, dose expansion, and efficacy expansion. Objective: To evaluate the objective response rate (ORR), safety and tolerability of the combination of SHR-1501 and adibelizumab in the treatment of advanced malignant tumors, and to provide the recommended dose (RP2D) for subsequent clinical studies.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-09.
Status change: Not Yet Recruiting → Recruiting 2026-01-20
Trial Details
NCT Number NCT07073534
Lead Sponsor Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions Patients With Advanced or Metastatic Malignant Tumors
Enrollment 203 participants
Start Date 2025-07-24
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-22